Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project

(2020) Inge M.W. Verberk et al.   NEUROBIOLOGY OF AGING

Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study

(2020) Frank de Wolf et al.   BRAIN

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

(2019) Andrea Vergallo et al.   Alzheimers & Dementia

Reversible Immuno-Infrared Sensor for the Detection of Alzheimer’s Disease Related Biomarkers

(2019) Brian Budde et al.   ACS Sensors

Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors

(2019) Hannah Stocker et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Amyloid blood biomarker detects Alzheimer's disease

(2018) Andreas Nabers et al.   EMBO Molecular Medicine

Amsterdam Dementia Cohort: Performing Research to Optimize Care

(2018) Wiesje M. van der Flier et al.   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes

(2018) Inge M.W. Verberk et al.   ANNALS OF NEUROLOGY

Optimizing Patient Care and Research: The Amsterdam Dementia Cohort

(2018) Wiesje M. van der Flier et al.   JOURNAL OF ALZHEIMERS DISEASE

Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study

(2018) Diego Albani et al.   JOURNAL OF ALZHEIMERS DISEASE

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

(2018) Rosalinde E. R. Slot et al.   Alzheimers Research & Therapy

An ATR–FTIR Sensor Unraveling the Drug Intervention of Methylene Blue, Congo Red, and Berberine on Human Tau and Aβ

(2017) Jonas Schartner et al.   ACS Medicinal Chemistry Letters

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

(2017) Shorena Janelidze et al.   JAMA Neurology

Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer’s Disease

(2016) Andreas Nabers et al.   ANALYTICAL CHEMISTRY

Reference measurement procedure for CSF amyloid beta (Aβ)1-42and the CSF Aβ1-42/Aβ1-40ratio - a cross-validation study against amyloid PET

(2016) Josef Pannee et al.   JOURNAL OF NEUROCHEMISTRY

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Amyloid imaging for dementia in clinical practice

(2015) John T. O’Brien et al.   BMC Medicine

An infrared sensor analysing label-free the secondary structure of the Abeta peptide in presence of complex fluids

(2015) Andreas Nabers et al.   Journal of Biophotonics

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

(2014) Frank Jessen et al.   Alzheimers & Dementia

Predicting Alzheimer disease with β-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

(2014) Christopher C. Rowe et al.   ANNALS OF NEUROLOGY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Affinity of copper and zinc ions to proteins and peptides related to neurodegenerative conditions (Aβ, APP, α-synuclein, PrP)

(2012) Izabela Zawisza et al.   COORDINATION CHEMISTRY REVIEWS

Subjective cognitive impairment

(2012) Robert Stewart   CURRENT OPINION IN PSYCHIATRY

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

(2012) Iryna Benilova et al.   NATURE NEUROSCIENCE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct three-dimensional visualization of membrane disruption by amyloid fibrils

(2012) L. Milanesi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Transformation of amyloid β(1–40) oligomers into fibrils is characterized by a major change in secondary structure

(2010) Rabia Sarroukh et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology